Harmony-HHT: ATV-1601 in Participants With Hereditary Hemorrhagic Telangiectasia (HHT) | MicrobiomeTrials← Back to trialsNCT07601425
Harmony-HHT: ATV-1601 in Participants With Hereditary Hemorrhagic Telangiectasia (HHT)
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2026-07-27Est. Completion: 2027-12
Enrollment target: 100 participants Locations- Arizona Pulmonary Specialists, Phoenix, Arizona, United States
- Augusta University Medical Center, Augusta, Georgia, United States
- Innovative Hematology, Indianapolis, Indiana, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- Mayo Clinic, Rochester, Minnesota, United States
- Washington University in St. Louis, St Louis, Missouri, United States
- University of Utah Health Sciences Center, Salt Lake City, Utah, United States
Other microbiome trials you might be interested in
Hereditary Hemorrhagic TelangiectasiaEpistaxisAnemiaNosebleedHHT
During the Efficacy Study (Part B), the investigators will study whether Pazopanib, taken daily for 24 weeks, will reduc…
Los Angeles, United StatesCompleted Nov 21, 2025
Hereditary Haemorrhagic Telangiectasia (HHT)
This observational study evaluates health-related quality of life (HR-QoL) in pediatric and young adult patients aged 2-…
Cincinnati, United StatesEst. completion Dec 2026